Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

201982 citationsJournal Article

Authors

Omid Hamid · Angeles Clinic and Research Institute

Luciana Molinero

Christopher R. Bolen

Jeffrey A. Sosman · Vanderbilt University

Eva Muñoz‐Couselo · Hebron University

Harriet M. Kluger · Yale Cancer Center

David F. McDermott · Beth Israel Deaconess Medical Center

John D. Powderly

Abstract

Atezolizumab was well tolerated, with durable responses and survival in patients with melanoma. PD-L1 expression, TMB, and Teff signatures may indicate improved benefit with atezolizumab in these patients.

Topics & Keywords

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 25, Issue 20, pp. 6061-6072

DOI: 10.1158/1078-0432.ccr-18-3488

Field-Weighted Citation Impact: 4.65